Evidence map›Paper›PMID 40586967›Full record

ReviewBiogerontology2025

Translational potential of GADD45α: biomarker and therapeutic target in age-associated neurodegeneration and longevity.

Imran Kazmi, Fahad A Al-Abbasi, Mustafa Zeyadi, Misbahuddin Rafeeq, Alaa Hamed Habib, Johar Iqbal, Sami I Alzarea, Omar Awad Alsaidan, Muhammad Shahid Nadeem

Abstract readReview
PubMed Publisher
In one paragraph

Review in Biogerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Imran KazmiDepartment of Biochemistry, Faculty of Sciences, King Abdulaziz University, 21589, Jeddah, Saudi Arabia. ikazmi@kau.edu.sa.
Fahad A Al-AbbasiDepartment of Biochemistry, Faculty of Sciences, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Mustafa ZeyadiDepartment of Biochemistry, Faculty of Sciences, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Misbahuddin RafeeqDepartment of Pharmacology Faculty of Medicine, Rabigh King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Alaa Hamed HabibDepartment of Physiology, Faculty of Medicine, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Johar IqbalDepartment of Basic Medical Sciences, Faculty of Medicine, Jazan University, 45142, Jazan, Saudi Arabia.
Sami I AlzareaDepartment of Pharmacology, College of Pharmacy, Jouf University, 72341, Sakaka, Aljouf, Saudi Arabia.
Omar Awad AlsaidanDepartment of Pharmaceutics, College of Pharmacy, Jouf University, 72341, Sakaka, Aljouf, Saudi Arabia.
Muhammad Shahid NadeemDepartment of Biochemistry, Faculty of Sciences, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aging features a gradual decline in genomic integrity, epigenetic fidelity, and cellular homeostasis, driving the onset of chronic pathologies such as cancer, neurodegeneration, and metabolic disease. Growth arrest and DNA damage-inducible 45 alpha (GADD45α) functions as a pivotal stress-response mediator, coordinating DNA repair, cell-cycle arrest, oxidative stress defence, mitochondrial quality control, and chromatin remodeling. Researchers have extensively studied GADD45α in tumor suppression, but its roles in healthy aging and age-related disorders remain underexplored. Here, we provide a comprehensive synthesis of recent findings illuminating GADD45α's contributions to aging biology. We detail its engagement with nucleotide and base excision repair pathways to preserve genome stability, enforce G₂/M checkpoints to prevent damaged DNA propagation, and promote mitochondrial resilience under oxidative challenge. We then examine how GADD45α modulates epigenetic landscapes, mitigating age-associated DNA methylation drift and sustaining chromatin plasticity, and highlight its emerging neuroprotective actions in Alzheimer's and Parkinson's models. Integrating multi-omics analyses, in vivo rodent investigations, and Drosophila lifespan assays, we establish GADD45α as a dynamic biomarker of cellular aging and a promising geroprotective target. Finally, we discuss translational strategies to harness GADD45α activity, ranging from small-molecule enhancers and epigenetic modifiers to precision gene-editing to reinforce DNA repair capacity, delay senescence onset, and extend organismal healthspan. This review reframes GADD45α from a cancer-centric effector to a versatile regulator of aging processes, underscoring its therapeutic potential for promoting healthy longevity.

Indexed as

AgingCell Cycle ProteinsLongevityNeurodegenerative DiseasesNuclear ProteinsAnimalsBiomarkersDNA RepairEpigenesis, GeneticGADD45 ProteinsHumansTranslational Research, BiomedicalBiomarkersCell Cycle ProteinsGADD45A protein, humanGADD45 ProteinsNuclear ProteinsAgingBiomarkers of agingEpigenetic regulationGADD45αLongevity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.